Tag:

Eli Lilly

Latest Headlines

Latest Headlines

What's next in diabetes drugs? The pulse of R&D at ADA14

Convening in San Francisco for the annual conference of the American Diabetes Association this weekend, drugmakers angled for the spotlight in a field made up mostly of similar treatments with small differentiations that could spell the difference between blockbuster sales and also-ran status.

Boehringer, Lilly creep up on Sanofi with Lantus biosimilar

Eli Lilly and Boehringer Ingelheim say their in-development Lantus biosimilar proved as safe and effective as its reference treatment across 6 clinical trials.

Lilly bets its diabetes drug dulaglutide can dominate a crowded class

Eli Lilly will hardly be the first in the field of GLP-1 treatments for diabetes if and when it launches dulaglutide, but the company believes its drug has the data to stand out among its rivals and claim the lion's share of a multibillion-dollar market.

Eli Lilly's key franchise drug ramucirumab flops in PhIII liver cancer study

Lilly has hit another setback in its effort to expand the market range for its key cancer drug ramucirumab, recently approved as Cyramza for stomach cancer.

Lilly's head-to-head with Victoza raises a red flag for diabetes drug dulaglutide

The abstracts for the upcoming scientific conference of the ADA hit Friday, and top analyst Mark Schoenebaum at ISI flagged a critical issue for Eli Lilly's top drug candidate dulaglutide that could come back to haunt the troubled pharma giant after it reaches the market with its GLP-1 contender.

Sanofi, Lilly prep OTC Cialis to compete against counterfeit ED pills

What's the best defense against all those fake versions of Viagra and other prescription erectile dysfunction pills that are sold online directly to men looking for a boost in the bedroom? Sanofi believes it has the answer: an over-the-counter version of Eli Lilly's ED blockbuster Cialis.

Lilly, Novartis and Pfizer join with Broad Institute for bioinformatics challenge

A clutch of Big Pharma companies is backing a competition to create predictive models that could lead to new targets for cancer drugs. Eli Lilly, Novartis and Pfizer are among the data funders of the competition, which calls for the development of models that show how essential a gene is to the survival of a cancer cell.

Boehringer Ingelheim, Eli Lilly can resubmit NDA for diabetes drug with warning letter resolved

Boehringer Ingelheim has finally received some good news for its manufacturing facility in Ingelheim, Germany. The FDA has notified it that it has closed out a warning letter for the facility.

FDA's OK for Boehringer Ingelheim plant gives it and Lilly hope on diabetes drug

Boehringer Ingelheim's manufacturing facility in Ingelheim, Germany has generated a lot of mail from the FDA. Finally, some good news: The company said today it received a letter from the FDA clearing the plant, meaning it and partner Eli Lilly can move forward with empagliflozin.

Eli Lilly gets on the trial transparency bandwagon

In keeping with changing industry standards, Eli Lilly has joined the host of drugmakers opening up their data vaults, going further than some but not quite baring it all.